The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2020 | New agents for EGFR+ NSCLC: osimertinib and beyond
Natasha Leighl, BSc, MMSc, MD, Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, Canada, discusses the emergence of the new EGFR inhibitor osimertinib following the FLAURA trial, highlighting the benefits and challenges of this. She explains the incidence of resistance and the potential mechanisms of this, such as EGFR C797S mutation. Next, she discusses exciting new trials and novel approaches in this group. This interview took place at the 18th British Thoracic Oncology Group (BTOG) 2020 congress, held in Dublin, UK.
